Latest Ratios: P/E Ratio -0.0x · EV/EBITDA 9.2x · ROE 21.4%. (2005–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3M | — | — | — | — | — | — | — | — | — | — |
| Enterprise Value | $3M | — | — | — | — | — | — | — | — | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.09 | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.00 | — | — | — | — | — | — | — | — | — | — |
| P/FCF | 10.78 | — | — | — | — | — | — | — | — | — | — |
| P/OCF | 7.41 | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | 9.17 | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | 11.71 | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 33.0% | 33.0% | 32.3% | 22.3% | 22.9% | 79.7% | 90.2% | 90.6% | 91.9% | — | — |
| Operating Margin | 8.4% | 8.4% | 5.6% | 2.2% | -2.1% | -613.0% | -151.9% | -302.3% | -124.9% | -6745.1% | 28.8% |
| Net Profit Margin | 7.8% | 7.8% | 7.2% | 0.6% | -3.6% | -575.1% | -377.1% | -631.8% | -136.3% | -6654.4% | 34.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 21.4% | 21.4% | 40.2% | — | -3.5% | -202.4% | -734.8% | -1063.7% | -452.3% | -567.6% | 164.4% |
| ROA | 8.5% | 8.5% | 9.2% | 1.0% | -1.9% | -109.1% | -207.2% | -254.8% | -244.4% | -342.4% | 105.6% |
| ROIC | 13.3% | 13.3% | 10.3% | 6.8% | -1.3% | -143.5% | -107.9% | -128.5% | -172.3% | -266.4% | 68.5% |
| ROCE | 20.9% | 20.9% | 23.9% | — | -1.9% | -203.6% | -150.2% | -207.7% | -414.3% | -575.3% | 116.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.32 | 0.32 | 0.29 | — | — | 0.06 | 0.23 | 3.10 | 1.00 | 0.67 | 0.58 |
| Debt / EBITDA | 1.05 | 1.05 | 1.91 | 7.31 | — | — | — | — | — | — | 0.33 |
| Net Debt / Equity | — | -0.29 | -0.08 | — | — | -1.17 | -1.30 | -0.55 | — | — | — |
| Net Debt / EBITDA | -0.95 | -0.95 | -0.50 | 7.28 | — | — | — | — | — | — | 0.28 |
| Debt / FCF | — | -1.01 | -0.41 | 2.16 | — | — | -10.30 | — | — | — | 6.51 |
| Interest Coverage | 16.10 | 16.10 | 4.17 | 1.23 | -0.26 | — | -8.63 | -6.75 | -9.17 | -37.77 | — |
Net cash position: cash ($575111) exceeds total debt ($302149)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.47 | 1.47 | 1.76 | 0.86 | 0.95 | 2.71 | 1.74 | 2.31 | 0.71 | 0.82 | 1.11 |
| Quick Ratio | 1.47 | 1.47 | 1.76 | 0.86 | 0.95 | 2.71 | 1.74 | 2.31 | 0.71 | 0.82 | 1.11 |
| Cash Ratio | 0.34 | 0.34 | 0.34 | 0.00 | 0.01 | 2.37 | 1.28 | 1.45 | 0.03 | 0.05 | 0.15 |
| Asset Turnover | — | 0.99 | 0.96 | 1.90 | 1.79 | 0.19 | 0.60 | 0.27 | 1.95 | 0.05 | 3.45 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 9.3% | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | — | — | — | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | — | — | — | — | — | — | — | — | — | — |
| Shares Outstanding | — | $846 | $7M | $7M | $7M | $486500 | $188650 | $1276 | $9479 | $5896 | $5960 |
Liquidity and Integration Uncertainty
Based on the reported P/S ratio of 1.11, the market appears to be pricing BTTC as a speculative micro-cap entity rather than a mature asset manager, reflecting significant uncertainty regarding the long-term revenue sustainability of the newly consolidated pharmaceutical and engineering business units following the July 2024 merger.
The current valuation multiples suggest that investors are discounting the company's future cash flows heavily, likely due to the lack of a proven track record for the combined entity. The absence of a meaningful P/E ratio further underscores the market's focus on top-line growth potential rather than current earnings, which remain volatile and distorted by non-operating items.
As reported in recent financial statements, the company's 32.98% gross margin reflects the high cost of service-heavy engineering operations, which, when combined with significant corporate overhead, results in an operating margin that appears strained compared to the typical profitability profiles of established pharmaceutical or technology firms.
The wide variance in quarterly margins suggests that the company is struggling to achieve economies of scale during its integration phase. Investors should monitor whether the shift toward higher-margin pharmaceutical royalties can eventually offset the labor-intensive costs currently dragging down the overall profitability of the TalenTec engineering segment.
According to the latest quarterly data, the ROIC of 14.8% in 2025Q4 represents a sharp, likely anomalous, reversal from the negative returns observed in previous quarters, suggesting that the company's capital efficiency is currently being driven by non-recurring accounting adjustments rather than sustainable operational performance.
The extreme volatility in ROE and ROIC metrics warrants caution, as these figures appear disconnected from the company's underlying business fundamentals. This instability suggests that the company has not yet established a consistent mechanism for compounding capital, making it difficult to assess the long-term value creation potential of the current management strategy.
Based on the reported cash reserves of $575,111, the company's liquidity position appears highly vulnerable, as this limited buffer may be insufficient to support the ongoing R&D requirements and cross-border operational costs identified in recent SEC filings, potentially necessitating near-term equity dilution to maintain business continuity.
The current ratio of 1.47 indicates a modest ability to cover short-term obligations, but the absolute level of cash is concerning given the complexity of the firm's dual-jurisdiction structure. Without a significant increase in recurring revenue, the company may face severe liquidity constraints if clinical or engineering milestones are delayed.
The most commonly misapplied metric for BTTC is the P/E ratio, which obscures the company's true operational reality by treating it as a traditional asset manager rather than a hybrid biotech-engineering firm, thereby failing to account for the heavy R&D and integration costs that currently dominate its financial profile.
Investors should instead focus on the revenue growth rate and the contract backlog within the engineering segment to gauge the company's underlying health. Relying on standard asset management valuation multiples likely leads to a fundamental misunderstanding of the company's risk-reward profile and its reliance on technical service fees to fund long-term pharmaceutical development.
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BTTC stock.
Black Titan Corporation's current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Black Titan Corporation's current EV/EBITDA is 9.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
Black Titan Corporation's return on equity (ROE) is 21.4%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -107.9%.
Based on historical data, Black Titan Corporation is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Black Titan Corporation has 33.0% gross margin and 8.4% operating margin.
Black Titan Corporation's Debt/EBITDA ratio is 1.0x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.